142 related articles for article (PubMed ID: 38043920)
1. A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study.
Dong J; Tao T; Yu J; Shan H; Liu Z; Zheng G; Li Z; Situ W; Zhu X; Li Z
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1925. PubMed ID: 38043920
[TBL] [Abstract][Full Text] [Related]
2. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
3. Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment.
Wang Y; Lu G; Xue X; Xie M; Wang Z; Ma Z; Feng Y; Shao C; Duan H; Pan M; Ding P; Li X; Han J; Yan X
Front Immunol; 2022; 13():903758. PubMed ID: 36016939
[TBL] [Abstract][Full Text] [Related]
4. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
5. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
6. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
7. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
[TBL] [Abstract][Full Text] [Related]
8. Construction of a lung adenocarcinoma prognostic model based on N6-methyl-adenosine-related long noncoding RNA and screening of potential drugs based on this model.
Hou Q; Zhong Y; Liu L; Wu L; Liu J
Anticancer Drugs; 2022 Apr; 33(4):371-383. PubMed ID: 35213857
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
11. Identification and verification of a prognostic ferroptosis-related lncRNAs signature for patients with lung adenocarcinoma.
Qi K; Liu XL; Chen XL; Song C; Peng JH; Xu JJ
Am J Transl Res; 2022; 14(6):3698-3715. PubMed ID: 35836852
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma.
Tian Q; Zhou Y; Zhu L; Gao H; Yang J
Front Cell Dev Biol; 2021; 9():684259. PubMed ID: 34307361
[No Abstract] [Full Text] [Related]
13. Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.
Zhang J; Song L; Li G; Liang A; Cai X; Huang Y; Zhu X; Zhou X
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17199-17213. PubMed ID: 37789154
[TBL] [Abstract][Full Text] [Related]
14. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
15. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
Zhou J; Wang X; Li Z; Jiang R
FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
[TBL] [Abstract][Full Text] [Related]
17. Identification of Clinical Prognostic Regulators and Analysis of Ferroptosis-Related Signatures in the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma.
Wang W; Cui G; Zhao S
Dis Markers; 2023; 2023():9155944. PubMed ID: 36845013
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
Sun D; Zhang C
Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
[TBL] [Abstract][Full Text] [Related]
19. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
20. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
